Double-Blind, Placebo-Controlled, Randomized Study Comparing 0.0003% Calcitriol with 0.1% Tacrolimus Ointments for the Treatment of Endemic Pityriasis Alba by Moreno-Cruz, Berenice et al.
Hindawi Publishing Corporation
Dermatology Research and Practice
Volume 2012, Article ID 303275, 6 pages
doi:10.1155/2012/303275
Clinical Study
Double-Blind, Placebo-Controlled, RandomizedStudy
Comparing 0.0003% Calcitriolwith0.1% TacrolimusOintments
for the Treatment of EndemicPityriasis Alba
Berenice Moreno-Cruz, Bertha Torres-´ Alvarez,
DianaHern´ andez-Blanco, and JuanPablo Castanedo-Cazares
Dermatology Department, Hospital Central “Dr. Ignacio Morones Prieto”, Universidad Aut´ onoma de San Luis Potos´ ı,
Avenida Carranza No. 2395, CP 78210, San Luis Potosi, Mexico
Correspondence should be addressed to Juan Pablo Castanedo-Cazares, castanju@yahoo.com
Received 1 December 2011; Revised 30 January 2012; Accepted 31 January 2012
Academic Editor: Iris Zalaudek
Copyright © 2012 Berenice Moreno-Cruz et al. This isan open access article distributedunder the CreativeCommons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Background. Pityriasis alba (PA) is a frequent cause of consultation in tropical areas due to its chronic course, frequent relapses,
and notorious hypopigmented lesions in pediatric dark skin populations. Currently, no treatment is widely accepted. Objective.
To assess the eﬃcacy of 0.0003% calcitriol and 0.1% tacrolimus ointments compared with placebo in the treatment of endemic
PA. Methods. Twenty-eight children aged 3–17 years with 56 symmetrical lesions and phototype IV-V, were randomly assigned
to receive the treatments on target lesions on the face. Improvement was evaluated at baseline and 8 weeks later clinically and by
digital quantiﬁcation of the aﬀected area, colorimetry, and transepidermal water loss (TEWL). Results. Tacrolimus and calcitriol
ointments induced a mean improvement of 68%, compared to 44% of placebo. We found an elevated TEWL in PA lesions. In
the treated plaques, the reduction of the aﬀected area was associated with improvement of pigmentation and TEWL. Conclusions.
Calcitriol and tacrolimus induced similar repigmentation in endemic PA lesions. Melanogenic, anti-inﬂammatory, and barrier
defect restoration properties of these drugs may explain these ﬁndings.
1.Introduction
Pityriasis alba (PA) is a benign inﬂammatory dermatosis
aﬀecting about 5% of pediatric population [1, 2]. Although
it has a worldwide distribution, it is frequently seen in
tropical areas of the world; therefore, it is more evident in
individuals with darker complexion, although it is present in
all skin types [1–5]. There are two types of PA, the endemic,
aﬀecting infants and children of low socioeconomic condi-
tions in developing countries, and atopic-dermatitis-related
PA which is associated with postinﬂammatory hypopigmen-
tation [6]. This entity has received many synonyms (i.e.,
chronic impetigo, erythema streptogenes). It is characterized
byhypopigmented,irregularplaqueswithwell-toill-deﬁned
borders, covered occasionally by ﬁne scales; it aﬀects mainly
face, limbs, and sometimes thorax [1–3]. Its etiology is
still unknown; although infectious mechanisms [3, 6], and
nutrient deﬁciencies [1, 7, 8] have been implicated, a causal
relationship has not been recognized. Excessive and unpro-
t e c t e ds u ne x p o s u r ei sc o n s i d e r e da ni n v o l v e df a c t o r[ 1, 2, 8].
Another important risk factor is xerosis [1, 2, 4, 5]. Studies
from stratum corneum of PA lesions have described defects
in hygroscopicity and water-holding capacity detectable by
water absorption-desorption test, this suggests that the con-
dition is consequent to a dermatitic change and its hypopig-
mentation may be a postinﬂammatory mechanism [9].
Treatment includes topical application of humectants
[1],corticosteroids[10],sunscreens[3],andantiseptics [10].
Recently, immunosuppressors (i.e., tacrolimus, pimecroli-
mus) have shown an excellent response in atopic related PA
[11, 12]. However, there are no clinical trials conﬁrming its
usefulness in endemic PA. Calcitriol (1,25-dihydroxyvitamin
D3) is an endogenous hormonally-active derivative of2 Dermatology Research and Practice
Table 1: Demographics, and clinical features of the 28 patients at
baseline.
Age (years), mean(SD) 10 (3.6)
Gender, n (%)
Male 15 (54)
Female 13 (46)
Phototype, n (%)
IV 7 (25)
V 21 (75)
Duration of PA (months)
Mean (SD) 9.6 (10.6)
Previous treatments, n (%) 10 (38)
Target lesions
Area (cm2), mean(SD) 3.9 (1.3)
L
∗ axis, mean(SD) 56.7 (2.7)
a∗ axis, mean(SD) 11.7 (1.5)
TEWL (g/m2/h), mean(SD) 14.9 (5)
vitamin D. Receptors for calcitriol in keratinocytes modu-
late diﬀerentiation and inﬂammation [13–17]. It activates
melanocytes, promotes melanin synthesis [18], and has
immunomodulation properties [16, 17]. These features may
be useful for the treatment of endemic PA. Adverse eﬀects
such as erythema and stinging have a low frequency [19],
and its use, compared with other therapeutic options, would
not imply a long-term carcinogenic risk or skin atrophy.
Therefore, we compared the eﬃcacy of the ointments of
0.1% tacrolimus, 0.0003% calcitriol, and the placebo for the
treatment of endemic PA.
2.MaterialandMethods
2.1.StudyDesign. Theinvestigationwasan8-week,random-
ized, double-blind, split-face placebo-controlled trial. The
study was conducted at the Dermatology department of the
Hospital Central of San Luis Potos´ ı, M´ exico (latitude 22◦09 
north,altitude1877meters).Informedconsentwasobtained
from patients and parents before entering the study, which
was approved by the local ethical committee. The trial is
registered at the US National Institutes of Health Clinical
Trial Register, with the number NCT01388517.
2.2. Patients. Patients from both genders, between 2 and 18
years old, attending our outpatient clinic, were included.
Subjects aﬀected by symmetrical lesions of PA on the face,
b e t w e e n2a n d6 c m 2were selected. Hypopigmented areas
on the face were initially evaluated, and target lesions were
identiﬁed for follow-up. Patients with other dermatosis,
including atopic dermatitis, and those who had used any
systemic or topical medication during the past 6 weeks were
excluded. The demographic data of the patients are shown in
Table 1.
2.3. Treatment. Topicals were set in similar containers and
patients were randomly assigned in a double-blind manner
to receive, 0.0003% calcitriol (Galderma, France), 0.1%
tacrolimus (Astellas Pharma, USA) or placebo (petrolatum,
Sigma Aldrich, USA) on target lesions. All subjects were
instructed to apply the treatment twice daily. Sunscreen was
not indicated, but the use of any type of cleanser or cosmetic
product on lesions was not allowed. All adverse eﬀects were
recorded.
2.4. Assessments. Patients were examined at 2, 4, 6 and 8
weeks. The primary outcome measure was the reduction of
the aﬀected area. Clinical improvement was appraised by
means of digital photographic registration (frontal, right,
and left views). Images were analyzed using the software
ImageJ v1.4, to quantify the dimension of target plaques.
As previously described, lesion was given a 0% score at
baseline, and a second percentage value was obtained at
the end of study [20]. An independent observer performed
a Physician Global Assessment (PGA), which was scored
as poor (0–25%), mild (26–50%), good (51–75%), and
excellent (>75%).
Pigmentary changes were objectively evaluated using a
colorimeter (Chromameter CR-300, Minolta, Osaka, Japan).
Coloration changes were examined by means of the L
∗
(luminosity), where 100 value is full white, and 0 total black;
and the a∗ (erythema) axis from 0 to 50. Improvement
was assessed by obtaining the L
∗ axis diﬀerence (L
∗Δ)
between the targeted lesional and perilesional areas (L
∗Δ =
lesional − perilesional). Skin that was at least 1cm away
from apparent lesion was considered perilesional. This was
performed for each visit during the study.
A secondary outcome measure included the evaluation
of the integrity of the cutaneous barrier, at baseline and
its modiﬁcation by treatments. Transepidermal water loss
( T E W L )w a sm e a s u r e db ya ne v a p o r i m e t e r( D e r m a l a b ,
Cortex Technology, Denmark). Water loss was recorded on
each plaque in g/m2/h. Prior to measurement, volunteers
were rested for at least 20min at 19–21◦Ci nar e l a t i v e
humidityenvironmentof40–45%.Cornealintegritychanges
were appraised by the TEWL diﬀerence between the targeted
lesional and perilesional areas (TEWLΔ = lesional −
perilesional).
2.5. Statistical Analysis. We calculated that a sample size of
16 lesions per intervention would detect a diﬀerence in the
PA improved area between the active treatments and control
of25%(i.e.,60%intreatmentsgroups,35%fortheplacebo),
assuming a SD of 25, at 95% CI, and two tails, α of 0.05
and β of 0.8. Therefore, 28 subjects with symmetrical lesions
were needed to ensure 48 evaluable lesions, considering a
dropout rate of 15%. Permuted block randomization was
used to assign treatments on lesions. Statistical analysis was
performed using analysis of variance, paired t test, χ2 test
(Fisher if n<5), and correlation tests with a level of
signiﬁcancesetat5%.PGAwasstandardizedusingthekappa
test of consistency. Tests were performed using the JMP
software 8.0 (Cary, NC, USA).Dermatology Research and Practice 3
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Figure 1: Mean percentage change in the depigmented area of PA
target lesions during the study for calcitriol (n = 19), tacrolimus
(n = 18), and placebo (n = 19). At 8 weeks, there were diﬀerences
among groups (one-way ANOVA, P< 0.001), but no diﬀerence
was noted between calcitriol and tacrolimus (t test, P = 0.9).
3. Results
The study recruited 28 children aﬀected by PA, with 19
lesionstoevaluateinthecalcitriolgroup,18inthetacrolimus
group, and 19 in the placebo group. The median age was 9
years (range 3–17 years). The demographics, mean duration
of PA, mean aﬀected area, and measure values are shown in
Table 1.
Reductions from baseline in PA lesions in the calcitriol
and tacrolimus groups, expressed as mean ± SD percentage
change, were signiﬁcantly higher than those obtained by
placebo from week 4 to week 8 (P ≤ 0.001). At the end of the
study, PA lesions were signiﬁcantly reduced in the calcitriol
and tacrolimus groups compared with the placebo group,
as demonstrated by the mean ± SD percentage change from
baselinelesion:68.2±24.7%,69.1±25.1%,and47.6±28.9%,
respectively (Figure 1). This data showed no statistical signif-
icance in the PA improved area for both drugs (P = 0.9).
With respect to the PGA score at the target lesions,
45.4%, 50% and 14.2% of the patients treated with calcitriol,
tacrolimus or placebo received a rating of excellent response
a tw e e k8( Figure 2). Altogether 40.9%, 40% and 23.8% of
patients in the respective interventions rated their lesions as
good. Therefore, there was a range of response from less than
20% to more than 90% in the three groups. Figures 3,a n d4
show lesions with excellent improvement by calcitriol and
tacrolimus.
At the end of the study, the average colorimetric changes
evaluated by the L
∗Δ showed signiﬁcant repigmentation in
the groups of lesions treated with calcitriol and tacrolimus
(P = 0.01, and P = 0.001 resp.). There was no diﬀer-
ence in the group of lesions treated with placebo (P =
0.09), (Table 2). In spite of these diﬀerences, we observed
a notorious relationship between the digitally measured
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Figure 2: Physician’s assessment of response at PA target lesions at
theendoftreatment(week8).Calcitriolandtacrolimuseﬃcacywas
rated equally for good and excellent response (P = 0.6, and P = 0.8,
χ2 test). Placebo response was signiﬁcantly lower compared to both
drugs in the former categories (P<0.001, χ2 test).
percentage of improved area, and the reduction in the L
∗Δ
values for calcitriol, tacrolimus and placebo. The correlation
coeﬃcients were r2 = 0.71 (P<0.001), r2 = 0.79 (P<
0.001), r2 = 0.79 (P<0.001), respectively.
PA lesions exhibited TEWL levels 30% approximately
higher than perilesional skin at the beginning of the study.
T h ea v e r a g eT E W Lv a l u ei nu n a ﬀected skin was 11.2 ±
3.2g/m 2/h, compared to PA values of 14.9±5g/m 2/h, 14.8+
5.6g/m 2/h, and 15.1 ± 4.8 in the calcitriol, tacrolimus and
placebo groups (P = 0.001). At 8 weeks, the mean TEWL
changes (TEWLΔ), denoted a signiﬁcant reduction in the
lesions treated with calcitriol and tacrolimus (P = 0.008,
and P = 0.01 correspondingly), but not in those treated
with placebo (P = 0.63). These data represented a mean
reduction of 67%, 57%, and 12.5% respectively in the TEWL
for calcitriol, tacrolimus and placebo.
We found a signiﬁcative relationship between repigmen-
tation and the reduction of TEWL in PA-treated lesions. This
was analysed by means of the values of TEWLΔ and L
∗Δ
for the calcitriol, tacrolimus and placebo-treated lesions. The
correlation coeﬃcients were r2 = 0.43 (P = 0.002), r2 =
0.56, (P = 0.003), and r2 = 0.54 (P = 0.004), respectively
(Figure 5).
Concerning side eﬀects, there was a transient complain
of burning sensation in 4 patients in the tacrolimus-treated
lesions. However, we did not observe visual erythema,
neither did we observe signiﬁcant changes in a∗ colorimetric
values (a∗Δ) on PA plaques, at baseline, during, or at the end
of the study for any of the interventions (Table 2).
4. Discussion
This is the ﬁrst study to describe the eﬃcacy of calcitriol
compared with tacrolimus or petrolatum as placebo for the
treatment of endemic PA in children patients. The study
showed that after 8 weeks of treatment the clinical eﬃcacy of4 Dermatology Research and Practice
Figure 3: PA lesion treated with 0.0003 % calcitriol in a 10-year-old girl, view at onset (left) and 8 weeks later (right). In the lower picture,
target lesion was outlined to measure the aﬀected area showing the excellent clinical response.
Figure 4: PA lesion treated with 0.1% tacrolimus ointment in a 7-year-old boy: onset and 8 weeks later with excellent improvement.
Table 2: Changes in repigmented area (%), colorimetric values (L∗,a ∗), and TEWL (g/m2/h) on target lesions of PA. Data are shown
initially, and at the end of study for calcitriol, tacrolimus and placebo.
0.0003% Calcitriol (n = 19) 0.1% Tacrolimus (n = 18) Placebo (n = 19)
Onset 8weeks P Onset 8weeks P Onset 8weeks P
Reduced area (%) 0 68.2(24.7) <0.001 0 69.1(25.1) <0.001 0 47.6(28.9) <0.001
L
∗Δ 4.2(4.3) 2.3(1.9) 0.01 4.1(1.1) 1.8(1.2) 0.001 4.3 (2.8) 2.7(2.2) 0.09
a∗ Δ −0.4(1.4) 0.1(2.1) 0.35 −0.5(1.5) −0.3(1.1) 0.65 0.4 (1.1) −0.2(1.6) 0.09
TEWL Δ 4.8(4.3) 1.6(1.3) 0.008 4(3.7) 1.7(1) 0.01 4 (4.1) 3.5(3) 0.63
Δ = lesional −perilesional values.
Data are expressed as mean, standard deviation in parenthesis.Dermatology Research and Practice 5
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Figure 5: Relationship and regression line between the repigmen-
tation of the PA aﬀected area, represented by the luminosity change
(L
∗Δ), and the corneal stratum integrity change represented by
the TEWL Δ for the three interventions. The relationship was
signiﬁcative (P<0.001) for all of them.
calcitriol was comparable to that of tacrolimus. The eﬃcacy
of petrolatum was also noticed, but was lower compared to
these active drugs.
It has been reported that tacrolimus is an eﬀective treat-
ment for atopic-related PA [11]. Therefore, current literature
suggests that PA etiology could be mainly inﬂammatory
[2, 9]. However, in our study the plaques of PA did not show
elevated redness colorimetric values (a∗) that could involve
major inﬂammation, but we found a signiﬁcantly impaired
permeability barrier in PA. TEWL as a marker of barrier
functionwasincreasedinallthePAlesionscomparedtonon-
apparent aﬀected skin. Interestingly, lesions that responded
to the interventions showing a pigmented increase simulta-
neously showed an important reduction in the TEWL. This
suggests that PA may have a local skin barrier defect that
may be associated to sebaceous glands atrophy and lipids
deﬁciency, which may contribute to the long duration and
frequent relapses [3, 4].
The improvement observed with calcitriol and tacro-
limus in PA patients could be explained by their regulatory
role in the melanocyte development and melanogenesis [18,
21, 22] and by an induced restoration of functional defects
of barrier due to intrinsic drug properties, in addition to the
protective eﬀect of the ointment vehicle mainly composed by
petrolatum, and not exclusively to their anti-inﬂammatory
properties. Besides these hallmarks and its cell-proliferative
regulation properties [14–17], topical calcitriol is able to
restore the epidermal permeability and antimicrobial barrier
via activation of the cutaneous vitamin D pathway and also
to increase epidermal and antimicrobial peptides [23]. These
pharmacological features could explain the improvement
seen in the calcitriol treated side.
Another signiﬁcant fact is that we neither indicated
sunscreen use, nor inﬂuenced sun exposure habits but we
observed notorious improvement; this suggests that most
importantfactorsotherthanUVradiationmightbeinvolved
in the pathogenesis of this condition. These results made us
wonder if steroids or immunosuppressors are justiﬁed for
this disease, besides considering its reported adverse eﬀects
(i.e., cutaneous atrophy, carcinogenic risk, or infections)
[24, 25].
Although PA has a chronic course, it has not been exten-
sively studied due to its self-limited and not so grave health
implications. Therefore, we have a lack of controlled studies
with limited knowledge about its therapy and pathogenesis.
Based on the results of our study, we could suggest that
calcitriol is at least as eﬀective as tacrolimus, and superior to
petrolatum in endemic PA, oﬀering some clinical advantages
to the pediatric population. Side eﬀects such as skin burning
sensationandimmunosupressionwouldbeabsentcompared
to tacrolimus, besides the potential of avoiding carcinogenic
risk.
These ﬁndings matched with the expectations exposed
in the theoretical frame, but require conﬁrmation in larger,
longer-term studies.
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